# Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients

> **NCT06421870** · PHASE3 · RECRUITING · sponsor: **Ain Shams University** · enrollment: 210 (estimated)

## Conditions studied

- Chronic Kidney Diseases

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab
- **DRUG:** Pentoxifylline 400 MG

## Key facts

- **NCT ID:** NCT06421870
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2025-05
- **Final completion:** 2025-07
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2024-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06421870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06421870, "Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06421870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*